Dr. Reddy's Laboratories is currently trading at Rs 1127.65, up by 1.10 points or 0.10% from its previous closing of Rs 1126.55 on the BSE.
The scrip opened at Rs 1131.85 and has touched a high and low of Rs 1136.15 and Rs 1122.10 respectively. So far 12489 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1420.20 on 21-Aug-2024 and a 52-week low of Rs 1120.01 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs 1174.80 and Rs 1122.10 respectively. The current market cap of the company is Rs 94371.46 crore.
The promoters holding in the company stood at 26.64%, while Institutions and Non-Institutions held 49.74% and 10.38% respectively.
Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) for API manufacturing facility (CTO-2) in Bollaram, Hyderabad. Earlier, the inspection was conducted by the United States Food & Drug Administration (USFDA) at this facility. The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3).
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: